1xbet 보너스 코드 Pharmaceutical Co., Ltd.
Bristol-Myers K.K.

1xbet 보너스 코드 Pharmaceutical Co., Ltd. and the U.S.-based company Bristol-Myers Squibb have agreed to end the co-promotion arrangements for the drug SPRYCEL^®(generic name: dasat1xbet 보너스 코드ib) 1xbet 보너스 코드 Japan, effective from February 27, 2015.

1xbet 보너스 코드 and Bristol-Myers Squibb established a global contract in April 2009 in the area of hematological cancers and have been co-promoting SPRYCEL^®for the treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia 1xbet 보너스 코드 Japan s1xbet 보너스 코드ce January 2011. Bristol-Myers K.K. cont1xbet 보너스 코드ues to promote SPRYCEL^®1xbet 보너스 코드 Japan

1xbet 보너스 코드 Pharmaceutical will continue to receive a specified collaboration fee for SPRYCEL net sales in the U.S., Europe^*, and Japan. There will be no decrease or other change in terms for the collaboration fee 1xbet 보너스 코드 Pharmaceutical receives as a result of the termination of co-promotion in Japan.

This change to the agreement is specific to Japan and independent of Bristol-Myers Squibb's partnership with 1xbet 보너스 코드 in the U.S. and Europe.

• Europe: 5 countries consist1xbet 보너스 코드g of France, Germany, Italy, Spa1xbet 보너스 코드 and the U.K.